BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36938650)

  • 21. Taxane-containing regimens for metastatic breast cancer.
    Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
    Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients.
    Nagano T; Yamada Y; Ikeda T; Kanki H; Kamo T; Nishigori C
    Cancer; 2007 Aug; 110(3):648-51. PubMed ID: 17582627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of Cytotoxic Chemotherapy in Metastatic Breast Cancer: Putting Taxanes in Perspective.
    Sachdev JC; Jahanzeb M
    Clin Breast Cancer; 2016 Apr; 16(2):73-81. PubMed ID: 26603443
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The treatment landscape of advanced angiosarcoma in Asia-A multi-national collaboration from the Asian Sarcoma Consortium.
    Chen TW; Pang A; Puhaindran ME; Maw MM; Loong HH; Sriuranpong V; Chang CC; Mingmalairak S; Hirose T; Endo M; Kawai A; Farid M; Tan SH; Goh WL; Quek R; Chan JCH; Leung AKC; Ngan RKC
    Cancer Sci; 2021 Mar; 112(3):1095-1104. PubMed ID: 33393133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of docetaxel in patients with paclitaxel-resistant advanced gastric cancer.
    Kondoh C; Takahari D; Shitara K; Mizota A; Nomura M; Yokota T; Ura T; Ito S; Kawai H; Sawaki A; Muro K
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1511-5. PubMed ID: 23064062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
    Mody MD; Gill HS; Saba NF
    JAMA Otolaryngol Head Neck Surg; 2016 Sep; 142(9):898-905. PubMed ID: 27389786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
    Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
    Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
    Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
    Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiosarcomas and taxanes.
    Penel N; Lansiaux A; Adenis A
    Curr Treat Options Oncol; 2007 Dec; 8(6):428-34. PubMed ID: 18066504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
    Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
    Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiation-induced angiosarcoma of the breast shows major response to docetaxel after failure of anthracycline-based chemotherapy.
    Mano MS; Fraser G; Kerr J; Gray M; Evans V; Kazmi A; Canney P
    Breast; 2006 Feb; 15(1):117-8. PubMed ID: 16473744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial.
    Nomura H; Aoki D; Michimae H; Mizuno M; Nakai H; Arai M; Sasagawa M; Ushijima K; Sugiyama T; Saito M; Tokunaga H; Matoda M; Nakanishi T; Watanabe Y; Takahashi F; Saito T; Yaegashi N;
    JAMA Oncol; 2019 Jun; 5(6):833-840. PubMed ID: 30896757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
    Oh WK; Manola J; Babcic V; Harnam N; Kantoff PW
    Urology; 2006 Jun; 67(6):1235-40. PubMed ID: 16765185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.
    Sonpavde G; Pond GR; Choueiri TK; Mullane S; Niegisch G; Albers P; Necchi A; Di Lorenzo G; Buonerba C; Rozzi A; Matsumoto K; Lee JL; Kitamura H; Kume H; Bellmunt J
    Eur Urol; 2016 Apr; 69(4):634-641. PubMed ID: 26264159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.
    Sonpavde G; Pond GR; Mullane S; Qu AQ; Di Lorenzo G; Federico P; Necchi A; Rosenberg JE; Bellmunt J; Choueiri TK
    Clin Genitourin Cancer; 2015 Jun; 13(3):250-6. PubMed ID: 25481485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of Cutaneous Angiosarcoma: an Update Review.
    Bi S; Zhong A; Yin X; Li J; Cen Y; Chen J
    Curr Treat Options Oncol; 2022 Feb; 23(2):137-154. PubMed ID: 35182299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiosarcoma: a study of 98 cases with immunohistochemical evaluation of TLE3, a recently described marker of potential taxane responsiveness.
    Shon W; Jenkins SM; Ross DT; Seitz RS; Beck RA; Ring BZ; Okuno SH; Gibson LE; Folpe AL
    J Cutan Pathol; 2011 Dec; 38(12):961-6. PubMed ID: 22050093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel and docetaxel in prostate cancer.
    Obasaju C; Hudes GR
    Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.